Preclinical performance of a pediatric mechanical circulatory support device: The PediaFlow ventricular assist device

• Published in: The Journal of thoracic and cardiovascular surgery Vol. 156; no. 4; pp. 1643 - 1651.e7
• Main Authors: Olia, Salim E., Wearden, Peter D., Maul, Timothy M., Shankarraman, Venkat, Kocyildirim, Ergin, Snyder, Shaun T., Callahan, Patrick M., Kameneva, Marina V., Wagner, William R., Borovetz, Harvey S., Antaki, James F.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01-10-2018
• Subjects: Age Factors; Animals; Animals, Newborn; biocompatibility; blood pump; Body Weight; Child, Preschool; congenital heart disease; continuous flow; Electric Power Supplies - adverse effects; Heart Failure - physiopathology; Heart Failure - therapy; Heart-Assist Devices - adverse effects; hemocompatibility; Hemodynamics; Hemolysis; Humans; Infant; Infant, Newborn; Materials Testing; Miniaturization; pediatric heart failure; Prosthesis Design; Prosthesis Implantation - instrumentation; Sheep, Domestic; Ventricular Function; blood pump; RBP; continuous flow; FDA; hemocompatibility; CF; biocompatibility; LV; NIH; RPM; pediatric heart failure; NHLBI; VAD; congenital heart disease; MCS; PF3; PF4
• ISSN: 0022-5223; 1097-685X; 1097-685X
• DOI: 10.1016/j.jtcvs.2018.04.062

The PediaFlow (HeartWare International, Inc, Framingham, Mass) is a miniature, implantable, rotodynamic, fully magnetically levitated, continuous-flow pediatric ventricular assist device. The fourth-generation PediaFlow was evaluated in vitro and in vivo to characterize performance and biocompatibility.
Supported by 2 National Heart, Lung, and Blood Institute contract initiatives to address the limited options available for pediatric patients with congenital or acquired cardiac disease, the PediaFlow was developed with the intent to provide chronic cardiac support for infants as small as 3 kg. The University of Pittsburgh–led Consortium evaluated fourth-generation PediaFlow prototypes both in vitro and within a preclinical ovine model (n = 11). The latter experiments led to multiple redesigns of the inflow cannula and outflow graft, resulting in the implantable design represented in the most recent implants (n = 2).
With more than a decade of extensive computational and experimental efforts spanning 4 device iterations, the AA battery–sized fourth-generation PediaFlow has an operating range of 0.5 to 1.5 L/min with minimal hemolysis in vitro and excellent hemocompatibility (eg, minimal hemolysis and platelet activation) in vivo. The pump and finalized accompanying implantable components demonstrated preclinical hemodynamics suitable for the intended pediatric application for up to 60 days.
Designated a Humanitarian Use Device for “mechanical circulatory support in neonates, infants, and toddlers weighing up to 20 kg as a bridge to transplant, a bridge to other therapeutic intervention such as surgery, or as a bridge to recovery” by the Food and Drug Administration, these initial results document the biocompatibility and potential of the fourth-generation PediaFlow design to provide chronic pediatric cardiac support.